Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis

Current Medical Research and Opinion

Volumn 22, Issue 5, 2006, Pages 919-928

  Iwamoto, Jun ^a   Takeda, Tsuyoshi ^a   Sato, Yoshihiro ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Mitate Hospital   (Japan)

Author keywords

Adverse events; Alendronate; Fracture; Postmenopausal osteoporosis; Risedronate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ETIDRONIC ACID; FLUORIDE; IBANDRONIC ACID; PARATHYROID HORMONE; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D;

BONE TURNOVER; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; HIP FRACTURE; HUMAN; INCIDENCE; OSSIFICATION; OSTEOPENIA; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; RISK FACTOR; RISK REDUCTION; SHORT SURVEY; TREATMENT OUTCOME; VERTEBRA FRACTURE;

ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; TREATMENT OUTCOME;

EID: 33745053158     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X100276     Document Type: Short Survey

References (74)

1. Ensrud KE, Thompson DE, Cauley JA, et al. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. J Am Geriatr Soc 2000;48:241-9
2. Kanis JA, Oden A, Johnell O, et al. The components of excess mortality after hip fracture. Bone 2003;32:468-73
3. Ettinger B, Black DM, Mitlak BH, et al. [Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators]. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. J Am Med Assoc 1999;282:637-45
4. McClung MR, Geusens P, Miller PD, et al. [Hip Intervention Program Study Group]. Effect of risedronate on the risk of hip fracture in elderly women. New Engl J Med 2001;344:333-40
5. Harris ST, Watts NB, Genant HK, et al. [Vertebral Efficacy with Risedronate Therapy (VERT) Study Group]. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. J Am Med Assoc 1999;282:1344-52
6. Reginster J, Minne HW, Sorensen OH, et al. [Vertebral Efficacy with Risedronate Therapy (VERT) Study Group]. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int 2000;11:83-91
7. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. J Arn Med Assoc 1998;280:2077-82
8. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41
9. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl J Med 2001;344:1434-41
10. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New Engl J Med 2004;350:459-68
11. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22
12. Chesnut III CH, Skag A, Christiansen C, et al. Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
13. Delmas PD, Recker RR, Chesnut III CH, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporosis Int 2004;15:792-8
14. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281-9
15. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87:1586-92
16. Epstein S. The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Cin Proc 2005;80:379-88
17. Oxford-Centre Evidence Based Medicine. Levels of evidence and grades of recommendation. http://www.cebm.net/levels_of_evidence.asp
18. Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-8
19. Wehren LE, Hosking D, Hochberg MC. Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis. Curr Med Res Opin 2004;20:525-31
20. Cranney A, Waldegger L, Zytaruk N, et al. Risedronate for the prevention and treatment of postmenopausal osteoporosis. Cochrane Database Syst Rev 2003;4:CD004523
21. Papapoulos SE, Quandt SA, Liberman UA, et al. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporosis Int 2005;16:468-74
22. Boonen S, Laan RF, Barton IP, et al. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporosis Int 2005;16:1291-8
23. Bone HG, Hosking D, Devogelaer JP, et al. [Alendronate Phase III Osteoporosis Treatment Study Group]. Ten years' experience with alendronate for osteoporosis in postmenopausal women. New Engl J Med 2004;350:1189-99
24. Mellstrom DD, Sorensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75:462-8
25. Rodan G, Reszka A, Golub E, et al. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 2004;20:1291-300
26. Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999;131:935-42
27. Stock JL, Bell NH, Chesnut III CH, et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 1997;103:291-7
28. Bagger YZ, Tanko LB, Alexandersen P, et al. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 2003;33:301-7
29. Meunier PJ, Delmas PD, Eastell R, et al. Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines [International Committee for Osteoporosis Clinical Guidelines]. Clin Ther 1999;21:1025-44
30. Nishizawa Y, Nakamura T, Ohta H, et al. [Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis Japan Osteoporosis Society]. Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J Bone Miner Metab 2005;23:97-104
31. Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 2002;77:1031-43
32. Lanza FL, Hunt RH, Thomson ABR, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000;119:631-8
33. Garnero P, Shih WJ, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-700
34. Johnell O, Scheele WH, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:985-92
35. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301
36. Chavassieux PM, Arlot ME, Reda C, et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;100:1475-80
37. Ruggiero SL, Mebrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaw associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:27-34
38. Lenz JH, Steiner-Krammer B, Schmidt W, et al. Does avascular necrosis of the jaw in cancer patients only occur following treatment with bisphosphonates? J Cranio-fac Surg 2005;33:35-403
39. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk-factors, recognition, prevention, and treatment. J Maxillofac Surg 2005;63:1567-75
40. Garnero P, Sornay-Rendu E, Claustrat B, et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000;15:1526-36
41. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996;11:1531-8
42. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-6
43. Bauer DC, Black DM, Garnero P, et al. [Fracture Intervention Trial Study Group]. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004;19:1250-8
44. Fujimoto K, Iwakiri R, Okamoto K, et al. Characteristics of gastroesophageal reflux disease in Japan: increased prevalence in elderly women. J Gastroenterol 2003;38(Suppl 15):3-6
45. Yamaguchi T, Sugimoto T, Yamada H, et al. The presence and severity of vertebral fractures is associated with the presence of esophageal hiatal hernia in postmenopausal women. Osteoporosis Int 2002;13:331-6
46. Perkins AC, Wilson CG, Frier M, et al. Oesophageal transit, disintegration and gastric emptying of a film-coating risedronate placebo tablet in gastro-oesophageal reflux disease and normal control subjects. Alimnet Pharmacol Ther 2001;15:115-21
47. Rizzoli R, Greenspan SL, Bone III G, et al. [Alendronate Once-Weekly Study Group]. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002;17:1988-96
48. Schniter T, Bone HG, Crepaldi G, et al. [Alendronate Once-Weekly Study Group]. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging 2000;12:1-12
49. Simon JA, Lewiecki EM, Smith ME, et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002;24:1871-86
50. Rosen CJ, Hochberg MC, Bonnick SL, et al. [The Fosamax Actonel Comparison Trial Investigators]. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005;20:141-51
51. Emkey R. Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. Med Gen Med 2004;6:6
52. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71:103-11
53. Harris ST, Watts NB, Li Z, et al. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 2004;20:757-64
54. Watts NB, Lindsay R, Li Z, et al. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporosis Int 2003;14:437-41
55. Shiraki M, Kushida K, Fukunaga M, et al. A double-masked multicenter comparative study between alendronate and alfa-calcidol in Japanese patients with osteoporosis. Osteoporosis Int 1999;10:183-92
56. Shiraishi A, Takeda S, Masaki T, et al. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res 2000;15:770-9
57. Dukas L, Bischoff HA, Lindpaintner LS, et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc 2004;52:230-6
58. Szulc P, Chapuy MC, Meunier PJ, et al. Serum undecarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 1993;91:1769-74
59. Szulc P, Chapuy MC, Meunier PJ, et al. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone 1996;18:487-8
60. Vergnaud P, Garnero P, Meunier PJ, et al. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab 1997;82:719-24
61. Hauschka PV, Lian JB, Cole DE, et al. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 1989;69:990-1047
62. The WHO Scientific Group. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser 2003;921:86-109
63. 2 in the treatment of postmenopausal osteoporosis. Curr Drug Safety 2006;1:87-97
64. 2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 2000;15:515-21
65. 2 (menatetrenone) for bone loss in patients with cirrhosis of the liver. Am J Gastroenterol 2002;97:978-81
66. Tanaka I, Ohshima K. Effects of menatetrenone, a vitamin K analogue, on prevention of vertebral fracture in corticosteroid-induced osteoporosis. J Bone Miner Res 2001;16(Suppl):S531
67. Godschalk MF, Downs RW. Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. J Bone Miner Res 1988;3:113-5
68. Shibata K, Takeda M, Ito A, et al. Ovariectomy-induced hyperalgesia and antinociceptive effect of elcatonin, a synthetic eel calcitonin. Pharmacol Biochem Behav 1998;60:371-6
69. Siris ES, Harris ST, Eastell R, et al. [Continuing Outcomes Relevant to Evista (CORE) Investigators]. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 2005;20:1514-24
70. Kung AW, Chao HT, Huang KE, et al. Efficacy and safety of raloxifene 60 mg/day in postmenopausal Asian women. J Clin Endocrinol Metab 2003;88:3130-6
71. Neele SJM, DeValk-DeRoo G, Roos JC, et al. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 2002;30:599-603
72. Ma YL, Bryant HU, Zeng Q, et al. New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 2003;144:2008-15
73. Black DM, Bilezikian JP, Ensrud KE, et al. [PaTH Study Investigators]. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. New Engl J Med 2005;353:555-65
74. Lecart MP, Bruyere O, Reginster JY. Combination/sequential therapy in osteoporosis. Curr Osteoporosis Rep 2004;2:123-30